

.----

.

bluebird bio

March 2024

NASDAQ: BLUE

forward-looking statements

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding our expectations for our programs and therapies, including but not limited to our manufacturing and commercialization plans, including the number of anticipated patient starts across our portfolio of therapies, our expectations for expansion of the QTC network, patient demand for our therapies, and our ability to establish commercial infrastructure to support timely, equitable access to our therapies; our ability to establish favorable coverage for our therapies, including our ability to successfully partner with payers; our anticipated cash runway; our expectations regarding our ability to access future tranches of our term loan facility, are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in our most recent annual Report on Form 10-K, as well as our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


pursuing Curative gene Therapies...

to give patients and their families more bluebird days

Only commercial gene therapy company with three FDA approved products



Momentum building with commercial launches; opportunity to deliver significant value for patients and shareholders




40

Patients potentially eligible for SKYSONA[™] for cerebral adrenoleukodystrophy




Deploying a validated, commercial strategy for LYFGENIA – informed by our real-world experience with ZYNTEGLO



QTC Network

62 Qualified Treatment Centers (QTCs) activated for ZYNTEGLO and quickly onboarding for LYFGENIA



100% of ZYNTEGLO QTCs have initiated the activation process for LYFGENIA

49 QTCs already receiving referrals for LYFGENIA

Anticipate continued **QTC network** expansion across portfolio in 2024

Activated ZYNTEGLO QTC*



Optimized QTC network designed to reach individuals living with SCD

STRONG DEMAND FOR GENE THERAPY

POISED TO MEET PATIENTS WHERE THEY ARE

>70%

of SCD patients¹ would consider gene therapy if recommended by their doctor²

80%

of providers want both LYFEGNIA and its competitor available at their institution³

95%

of SCD patients² are within 200 miles of a planned QTC³

88%

of target SCD patients are actively being treated in the healthcare system⁴

Access & Reimbursement

Value of ZYNTEGLO is recognized

Patients with beta-thalassemia are achieving access



Validated access and reimbursement strategy designed to enable timely, equitable access to LYFGENIA for sickle cell disease

\$3.1M price tied to value

Demonstrated robust and sustained clinical benefit (out **more than 5** years)

Reflects lifetime impact of reducing or eliminating VOEs

- Healthcare utilization
- Future earnings
- Life opportunities

Outcomes-based agreement offerings

Meaningful risk sharing

Tied to VOE related hospitalizations

Patients followed for **3 years**

Commercial payer and Medicaid options designed to offer predictability and operational ease



Encouraging payer interactions


Signed outcomes-based agreements representing >200 million covered lives

Discussions ongoing with >15 Medicaid agencies representing ~80% of individuals with SCD in the US¹

Active engagement with CMMI on innovative payment demonstration (anticipated 2025)

Treatment Experience

LYFGENIA supported by the most robust and longest follow-up of any gene therapy program for SCD



* Death, due to significant baseline SCD-related cardiopulmonary disease; not considered related to lovo-cel.

Data as of Feb 13, 2023


*54 patients initiated cell collection in HGB-206 Group A, Group B and Group C. ^a sVOE is defined as a VOE requiring a hospitalization or multiple visits to an emergency department/urgent care over 72 hours and receiving intravenous medications at each visit; all VOEs of priapism requiring any level of medical attention were also considered sVOEs

Clinical Data Supporting LYFGENIA

- Label based on efficacy data from 36 patients from HGB-206 Group C (median 38 months follow-up) and safety data from 54 patients*
- February 13, 2023 data cut showing:
 - 32 patients evaluable for VOE endpoints including 8 adolescent patients
 - 94% complete resolution of severe VOEs in the
 6-18 months post infusion
 - 88% resolution of VOEs in the 6-18 months post infusion
 - Maintenance of VOE resolution in majority of patients through long-term follow up + stable production of HbA^{T87Q}
 - 100% of patients with history of stroke (n=5) remained free of recurrent stroke posttreatment with LYFGENIA
 - Majority of AEs attributed to underlying SCD or conditioning with busulfan
 - The label includes a Boxed Warning for hematologic malignancy

Delivering a consistent manufacturing process is essential for patients, families and providers

ZYNTEGLO[™] and LYFGENIA[™] use a similar manufacturing process with distinct supply chain and release criteria





QTC: Qualified Treatment Center; CMO: Contract Manufacturing Organization. Stage 2 release time an estimate based on release criteria per product label

Differentiated attributes of LYFGENIA that matter to patients, payers and providers



Underpinned by clinical attributes – including >5 years of follow up, in-depth safety analyses, and data addressing SCD complications, including stroke

Experienced commercial gene therapy team wellpositioned to lead in hemoglobinopathies

1 Potential multi-billion dollar opportunity

with ~22,000 addressable patients in the US; established commercial strategy and projected patient and physician demand

- 2 Significant commercial head start leveraging ZYNTEGLO launch synergies – same treating physicians, same QTCs, same payers
 - **Recognized gene therapy leader**

with deep gene therapy expertise, manufacturing experience and commercial infrastructure

SKYSONA[™]

SKYSONA[™] for cerebral adrenoleukodystrophy





Commercial

- SKYSONA is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)
- 8 patient starts since launch*; 5 QTCs activated; zero ultimate denials across government and commercial payers

<u>Clinical</u>

- 67 patients treated across all clinical trials
- Accelerated approval based on post-hoc analysis of 11 patients; estimated 72% likelihood of major functional disability free survival at 24 months
- Multiple boys treated with SKYSONA have developed hematologic malignancy and the label includes a boxed warning.**

Patient starts is defined as a cell collection (apheresis); Activated QTC defined as Qualified Treatment Center with a signed MSA. *Patient starts as of March 25, 2024 **bluebird closely monitors potential and diagnosed cases of hematologic malignancy in patients treated with SKYSONA and additional cases are expected to arise over time. bluebird is communicating regularly with treating physicians and regulatory authorities.

Closing

Established gene therapy leader poised to deliver shareholder value

Established Clinical Leadership

- 10+ years of gene therapy research
- 200+ patients treated
- 8 clinical trials

Demonstrated Regulatory Success

- Established track record for LVV platform
- 3 FDA-approved gene therapies

Commercial Gene Therapy Leader

- Scaled for 3 commercial launches
- Synergistic transplant and cell therapy infrastructure
- Proven reimbursement

85-105 patient starts¹ combined across LYFGENIA, ZYNTEGLO and SKYSONA anticipated in 2024

Current Financial Position



unaudited cash, cash equivalents, restricted cash & marketable securities balance as of December 31, 2023²

Up to \$175M


secured in debt financing in Q1 2024

21

Cash runway through Q1 2026³

1. Patient start defined as cell collection; 2. Cash balance contains \$53 million in restricted cash; 3. Cash runway is calculated using the cash balance / net burn rate (cash from revenue less cash paid for expenses) and is inclusive of cash, cash equivalents and marketable securities and excludes restricted cash; cash runway is based on launch estimates and current business plans, and assuming three tranches totaling \$125 million are executed from loan facility.

bluebird occupies a unique strategic position as a standalone gene therapy company



- 3 commercial launches
- Transplant and cell therapy infrastructure
- Proven reimbursement

